John A. Stalfort III - 29 May 2024 Form 4 Insider Report for Taysha Gene Therapies, Inc. (TSHA)

Role
Director
Signature
/s/ Kamran Alam, Attorney-in-Fact
Issuer symbol
TSHA
Transactions as of
29 May 2024
Transactions value $
$0
Form type
4
Filing time
31 May 2024, 16:18:25 UTC
Previous filing
16 Aug 2023
Next filing
10 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TSHA Common Stock Award $0 +49.2K +4.69% $0.00 1.1M 29 May 2024 Direct F1
holding TSHA Common Stock 884K 29 May 2024 See footnote F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TSHA Stock Option (right to buy) Award $0 +98.4K $0.00 98.4K 29 May 2024 Common Stock 98.4K $3.17 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents a restricted stock unit ("RSU") award. The RSUs will vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.
F2 The securities are held by Gineane Holly Stalfort, as Trustee of the John A. Stalfort III 2018 Irrevocable Trust under agreement dated as of October 25, 2018.
F3 The shares vest on the earlier of May 29, 2025 or the next annual stockholders meeting, subject to the Reporting Person's continued service as a director through the applicable vesting date.